ACVR2B (ACE-031) 10mg/vial

ACVR2B (ACE-031) 10mg/vial

Information about ACVR2B (Ace-031) 10 mg Bio-Peptide

This preparation takes a leading position among popular products containing the active substance Ace-031. Its unique effect on myostatin promotes intensive muscle growth and effective weight loss, creating a “drying” effect. You can order Ace-031 10 mg from the company Bio-Peptide in the form of an injectable solution without a prescription in our online pharmacy. ACVR2B (ACE-031) 10mg/vial.

Pharmacological action

This peptide actively blocks myostatin, which naturally slows down the growth of muscle tissue. The use of the drug stimulates an increase in muscle mass and significantly improves physical fitness, which is extremely important for athletes. Ace-031 10 mg is popular even among professional athletes preparing for competitions. Our studies confirm the high efficiency of this peptide for active acceleration of recovery processes after intensive training. ACVR2B (ACE-031) 10mg/vial.

Course and dosage of ACVR2B (Ace-031) 10 mg Bio-Peptide

The intake programme and recommended dosage should be individualised under the supervision of a sports doctor. Taking into account the unique features of the body and the goals set, it is important to draw up an individual programme. Typically, the product should be taken at a dose of 100 to 300 mg weekly, dividing the dose into several injections over the course of a week. ACVR2B (ACE-031) 10mg/vial.

Possible side effects and prevention of overdose

The following side effects may occur with a possible overdose :

1. Allergic reactions such as rashes and redness.
2. Abrupt fluctuations in blood pressure.
3. Pain and itching in the area of the injection.
4. Blood clotting disorders – both increases and decreases.
5. Risk of rupture of muscle tissue during high physical activity.
6. Headache.
7. Digestive disorders.

Contraindications to use ACVR2B (Ace-031) 10 mg Bio-Peptide

Contraindications include:

1. Individual intolerance to the components of the drug.
2. Pregnancy.
3. Oncological diseases.
4. Age under 18 years.